Yahoo
NYSE - Delayed Quote USD

Cencora, Inc. (COR)

330.84 +0.31 (+0.09%)
At close: 4:00:03 PM EDT
330.84 0.00 (0.00%)
After hours: 4:11:59 PM EDT
Trade Cencora on Coinbase
Chart Range Bar
Loading chart for COR

What's happening with COR?

13m ago
Powered by Yahoo Scout

Cencora is scheduled to report fiscal fourth-quarter results on November 4 before the market opens. Analysts expect revenue growth and stronger earnings, while the planned $2.4 billion American Oncology Network acquisitionadds a major strategic and financing consideration.

Powered by Yahoo Scout
  • Previous Close 330.53
  • Open 336.79
  • Bid 330.35 x 12000
  • Ask 330.40 x 4000
  • Day's Range 330.20 - 340.19
  • 52 Week Range 244.82 - 377.54
  • Volume 1,317,138
  • Avg. Volume 1,310,498
  • Market Cap (intraday) 63.133B
  • Beta (5Y Monthly) 0.58
  • PE Ratio (TTM) 24.56
  • EPS (TTM) 13.47
  • Earnings Date Nov 4, 2026
  • Forward Dividend & Yield 2.40 (0.73%)
  • 1y Target Est 369.08
  • Morningstar Rating Rating available with Stock Picks access

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.

www.cencora.com

47,000

Full Time Employees

September 30

Fiscal Year Ends

Healthcare

Sector

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

COR
1.46%
S&P 500 (^GSPC)
10.73%

1-Year Return

COR
2.30%
S&P 500 (^GSPC)
11.11%

3-Year Return

COR
82.97%
S&P 500 (^GSPC)
81.91%

5-Year Return

COR
188.13%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 84.75B
Earnings 763.52M
Profit Margin 0.90%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
20B
40B
60B
80B
0.0%
0.5%
1.0%
1.5%
2.0%

Analyst Insights

View More

Top Analyst

Baird
57/100
Latest Rating
Outperform

Analyst Price Targets

330.00
369.08 Average
330.84 Current
400.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/30/2026
Analyst Morgan Stanley
Rating Action Maintains
Rating Overweight
Price Action Raises
Price Target 346 -> 377

Statistics

View More

Valuation Measures

Annual
As of 10/29/2026
  • Market Cap

    63.07B

  • Enterprise Value

    72.17B

  • Trailing P/E

    24.54

  • Forward P/E

    16.61

  • PEG Ratio (current)

    4.75

  • Price/Sales (ttm)

    0.19

  • Price/Book (mrq)

    20.67

  • Enterprise Value/Revenue

    0.22

  • Enterprise Value/EBITDA

    14.13

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.79%

  • Return on Assets (ttm)

    3.56%

  • Return on Equity (ttm)

    96.87%

  • Revenue (ttm)

    332.77B

  • Net Income Avi to Common (ttm)

    2.62B

  • Diluted EPS (ttm)

    13.47

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.82B

  • Total Debt/Equity (mrq)

    446.52%

  • Levered Free Cash Flow (ttm)

    2.04B

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

330.84 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

Research Reports

View More
  • Cencora: Doubles Down on Oncology With AON Acquisition; Fair Value Estimate Maintained

    Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.

  • Raising target price

    Headquartered in Conshohocken, Pennsylvania, Cencora, formerly AmerisourceBergen, is one of the nation's largest pharmaceutical distributors. The company has 47,000 employees. The COR shares are a component of the S&P 500.

  • As has been the case for several weeks now, it is hard to argue

    As has been the case for several weeks now, it is hard to argue with the insider-sentiment data from Vickers Stock Research. With the caveat that transaction volume remains low due to trading restrictions during earnings season, we can pick any of the data points from Vickers and like what we see. When it comes to the one-week sell/buy ratios for indices, all of the major ratios from Vickers this week are lower (better) than they were last week, and that has kept all of the eight-week ratios in a trend that has been improving since August. On a sector basis, eight of the one-week sector ratios are currently bullish, two are neutral, and only one is bearish (with a mere five transactions in that sector). Turning to the eight-week sector ratios, nine sectors are bullish, two are neutral, and none are bearish. Indeed, there has not been a bearish eight-week ratio logged since August 24. Digging deeper, among the one-week sector ratios, the bullish sectors include the Consumer Discretionary, Consumer Staples, Financial, Healthcare, Industrial, Materials, Real Estate, and Utilities sectors. Meanwhile, the Energy and Information Technology sectors are neutral and the Communication Services sector is bearish. On an eight-week basis, the Communication Services and Information Technology sectors are both neutral, while all other sectors are bullish. In terms of movement between ratings, the Industrial and Materials sectors both improved their eight-week ratios from neutral to bullish over the past week. This week, analysts at Vickers highlighted insider transactions of interest at Pampa Energia S.A. (NYSE: PAM) and PepsiCo Inc. (NGS: PEP).

  • Cencora: Walgreens Volume Disruption Raises New Concern, but We Make No Changes for Now

    Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: